Some of you may have noted an earlier message that said: "This does not bode well for NPHC," or something like that. It was in reference to a Nov 3 release. Below is my email to NPHC investor relations and their response which came back to me in less than 15 minutes.
---------------
To whom it may concern:

Could you please respond to this recent news release from Nov 3, 2009?
http://www.marketwire.com/press-release/...

The title is: "NanoLogix Files International Patent Applications, Reclaims 18 Existing Patents, Noted in Department of Defense Quarterly Publication and Provides Operations Update."

In the body it says: "The company has reclaimed full rights to 18 patents previously licensed to Nutra Pharma Corporation after failure of Nutra
Pharma to pay the balance of patent royalties due for 2008 and the first half of 2009. Nutra Pharma was served notice of their default in July. NanoLogix has returned the 18 patents to the company portfolio and will pursue development and marketing of select technological aspects of the patents."

Could you respond what 18 patents they are referring to, and what if any impact this has on your first product release (Cobroxin & Nyloxin), as well as your other ongoing pipeline studies such as for MS and other diseases?
----------
Response:

Dear Dr. -----,

We chose to let go of those patents several months ago, as we were not working with them and they were not material to the Company. Additionally, we did not want to continue paying hefty royalties to NanoLogix for the rights to use those patents. We are continuing to use the 11 patents we own for the test kit technology.

Best regards,
David

David M. Isserman
Nutra Pharma Corp.
Toll-Free: (877) 895-5647
Web: http://www.NutraPharma.com
Blog: http://www.NutraPharma.com/blog
----------

This shows two things:
1. The news release about NanoLogix reclaiming 18 patents from NPHC has NO impact on Cobroxin/Nyloxin, nor any of the other pipeline research or test kits -- I repeat no impact.

2. NPHC management and IR are really on top of things. In an earlier post a basher criticized Rik Deitsch for having read such boards like iHub. If you heard the CC everyone's raving about, you know as a long term investor that this only proves the CEO is concerned to destroy unfounded accusations/bashing (and did so beautifully), and is concerned to increase shareholder value.

Kudos to NPHC management and IR.

GreenMan